You just read:

U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

News provided by

The Janssen Pharmaceutical Companies of Johnson & Johnson

Jan 28, 2019, 07:05 ET